Expanded White House Policy Could Stifle FDA’s Industry Advice

May 1, 2019

A recent White House oversight policy change could gum up the Food and Drug Administration’s (FDA) day-to-day work and hurt industry’s ability to stay in compliance, lawyers told Bloomberg Law.

Related Stories